---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-061028"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2026-05-26T20:15:40+00:00"
generated_at: "2026-05-26T20:33:27.755080+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Neuphoria receives AUD 1.416M CTx CRC payment; eligible for ~4.65% of $460M milestones

## Summary
- Received AUD 1.416M from CTx CRC upon Pfizer's Phase III start in ER+/HER2- metastatic breast cancer.
- Believes eligible for ~4.65% of future milestone payments from CTXT, total estimated at USD 460M across all parties.
- Total distributions received from CTx CRC since 2016: AUD 3.52M.
- Historical licensing revenues include AUD 967K from MSD (PRMT5) in 2016 and multiple Pfizer-related payments.
- Company is a passive party and cannot determine whether future milestones will be achieved or payment amounts.

## SEC filing metadata
- accession: 0001213900-26-061028
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2026-05-26T20:15:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/0001213900-26-061028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/ea0292160-8k_neuphoria.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-061028
- JSON: https://secwatch.observer/filing/0001213900-26-061028.json
- Plain text: https://secwatch.observer/filing/0001213900-26-061028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.